Antimicrobial resistance is a global health emergency.
The growing number of drug-resistant pathogens is making common infections more and more difficult to treat.
Gram-negative bacteria, a major cause of infections in recent years, are resistant to almost all antibiotics, leaving no option for treatment at all. BREAKthrough is a Doctoral Network which aims to make these bacteria susceptible to today’s standard-of-care antibiotics.
Since the bacteria’s outer membrane prevents antibiotics from entering the cell, the project will develop new compounds that ultimately damage the outer membrane and allow antibiotics to break through the bacterial cell wall.
BREAKthrough is funded under Horizon Europe’s Marie Skłodowska-Curie Actions (MSCA) programme.
We aim to fight gram-negative bacteria by developing inhibitors of protein machineries that help maintain the bacteria’s outer membrane.
We will provide 11 doctoral candidates with scientific, technical, business, and transferable skills to become professional drug developers.
BREAKthrough is an international, multi-disciplinary, and academic-industrial collaboration, involving experts from various scientific fields.